ENFORCE

Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 Vaccines

Monthly Report

Report number: 11

Date Report: 28th February 2023

Date of data extract: 23rd February 2023

Report prepared by: The ENFORCE Consortium

Approved by: ENFORCE Scientific Steering Committee

This report is an edited version of the confidential report generated for distribution and review to the Danish Medicines Agency only. Tables and figures with small numbers (<5 participants per cell) or very specific details and where there is the potential that individual participants could be identified or be able to identify themselves have been removed or edited to maintain participant confidentiality.

Contents

ENFORCE
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

Summary of key changes from previous report

This report provides an update to the previous report focusing on individuals who have received either a 4th or 5th dose of a SARS-CoV-2 vaccine.

The data presented in this report are presented either by the number of vaccine doses a participant has received or by the type of vaccine received when considering specific doses.

For the 4th and subsequent doses, the vaccine types have been split into three groups:

1. Original: This includes the wild-type Original Pfizer-BioNTech and Original Moderna vaccines
2. Bivalent BA.1: This includes the bivalent vaccines Pfizer-BioNTech Original/Omicron BA.1, and Moderna Original/Omicron BA.1
3. Bivalent BA.4-5: This includes the bivalent vaccines Pfizer-BioNTech Original/Omicron BA.4-5

Enrolment and study visits

The characteristics of individuals enrolled in the study are presented by the number of vaccine doses they had received at the time this report was generate.

The number of participants who have returned for their 2 year study visit is also included in this report.

Outcomes

The results of the X and Xc study visits for individuals receiving a 4th or 5th dose of SARS-CoV-2 vaccine are presented in this report. In addition to the original mesoscale assay, this report also contains results from the Meso Scale Serology Omicron assay which quantifies total IgG to six SARS-CoV-2 antigens: Spike (wildtype), Spike (B.1.1.529: BA.1), Spike (B.1.1.529: BA.2), Spike (B.1.1.529: BA.3), Spike (B.1.1.529: BA.4) and Spike (B.1.1.529: BA.5). These results are available for individuals having a study visit from October 2022 onwards.

The serology data for participants at their 2 year study visit is not yet available but will be included in subsequent reports as it accumulates.

Safety and Monitoring

Local and systemic reactions reported after the 4th and 5th vaccine doses are included in this report. This report also includes all SAEs and AE's reported following receipt of either a 4th or 5th vaccine dose. To shorten the report, the summary tables and overview of all AEs and SAEs occurring from the first 3 doses and reported previously are not included in this report. These can be found in the previous reports and can also be added back into future reports as required. It should also be noted that a number of participants may have received influenza and pneumococcal vaccines at the same time as their 4th and 5th vaccine doses. We are currently unable to identify how many participants this relates to and so the safety outcomes reported here are potentially confounded by simultaneous vaccinations.

Methods

The data presented in this report are descriptive. A detailed statistical analysis plan will be developed prior to any formal analysis being conducted.

Data sources

The data used to generate this report are based on the data stored in REDCap from the case report forms (CRFs) and online symptoms form. Data on serum antibody quantification using ELISA (Wantai) was provided by the SSI and the multiantigen serological tests by Aarhus University Hospital.

Information on the type of vaccines received and the dates of vaccinations were initially collected and reported though the study CRFs. This has now been validated via data from the Danish Vaccine Register (DDV), with the DDV considered the gold standard where discrepancies have arisen.

Data on any SARS-CoV-2 PCR-tests or SARS-CoV-2 antibody measurements were extracted from the surveillance system Key Infectious Diseases System (KIDS) (Statens Serum Institut, Copenhagen, Denmark).

Data on deaths are reported from two sources, as a serious adverse event (SAE) on the CRF and recorded in REDCap or through the Danish Civil Registration System (CPR). The CPR registry is a national register containing basic personal information, including dates of the deaths for all persons in Denmark who have a CPR number.

Definitions

In this version of the report the type of vaccine received, and date of vaccination is based on information provided from the DDV. Participants who received a first dose of Janssen were classed as having received a booster dose if they had at least one subsequent dose of an mRNA vaccine.

Results from the ELISA detection of total serum Ig to the Receptor Binding Domain (Wantai) were recorded as Negative (ratio <0.9), Positive (ratio >1.1), or inconclusive (ratio between 0.9-1.1). The ratio was calculated as the OD value/cut-off, where the cut-off= average of the negative controls +0.16. If the average is below 0.03 then the cut-off is set to 0.16 + 0.03. For manual execution the cut-off will almost always be 0.19.

For the multiantigen serological tests, the geometric mean and 95% confidence intervals (CI) for the antibody levels against the Receptor Binding Domain, the complete Spike protein and the Nucleocapsid at each study visit are reported. The calibration curve used to calculate antibody concentrations are performed by fitting the signals from the calibrators in a 4-parameter sigmoidal dose-response model. Antibody concentrations can then be determined from their ECL signals by backfitting to the calibration curve. To better evaluate the response to the bivalent vaccines, in addition to the original mesoscale assay, this report also contains results from the Meso Scale Serology Omicron assay which quantifies total IgG to six SARS-CoV-2 antigens: Spike (wildtype), Spike (B.1.1.529: BA.1), Spike (B.1.1.529: BA.2), Spike (B.1.1.529: BA.3), Spike (B.1.1.529: BA.4) and Spike (B.1.1.529: BA.5). These results are available for individuals having a study visit X or Xc from October 2022.

Breakthrough infection was defined as a positive SARS-CoV-2 PCR test result reported in the KIDS dataset after the date of first vaccination. The timing of the infection was based on the date of first positive test.

ENFORCE
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

A complete list of the AEs and SAEs reported after the 4ᵗʰ and 5ᵗʰ vaccine doses is provided. All SAEs and AEs are coded using MedDRA and are presented using the preferred terms and ordered alphabetically by system organ class.

Enrolment

The section gives an overview of the status of participants in the study. Table 1 outlines the number of participants enrolled in the study and reasons for exclusion in this report.

Table 1 Summary of participants enrolled in the study

Total included	Reason for exclusion
6972	All patients
6949	Consent withdrawn and requested data deleted
6949	Provided informed consent
6949	Missing enrolment date
6948	Aged under 18
6948	Vaccine not recommended
6948	Vaccinated Previously
6948	Agrees to follow protocol
6948	No SSI vaccine data (consent withdrawn) and expected to receive AZ after 10/3/21
6947	No SSI vaccine data (consent withdrawn) and only one study visit (enrolment)
6947	No SSI vaccine data (consent withdrawn) and no study visit after second vaccine
6943	Non-standard vaccine regimen*

*Non-standard regimens included AstraZeneca only, and a combination of Pfizer-BioNTech and Moderna for the first and second dose.

Demographics by number of vaccine doses received

All participants have now been under follow-up for between 18 and 24 months. Figure 1 shows the number of vaccine doses participants have received over time. Table 2 gives an overview of the participant demographics by the number of vaccine doses received at the time of most recent data extraction. The majority of the cohort, 5411 (78%) participants, have now received at least four doses of vaccine.

Figure 1 Number of vaccine doses participants have received over time

ENFORCE
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

From Table 2 , individuals who have received at least 5 doses of vaccine are those at increased risk and mainly aged ≥ 65 years old. Those who have only received 2 or 3 doses are mainly younger individuals (aged <55 years old).

Table 2 Participant demographics at study enrolment by number of vaccine doses received

| | Current vaccine status | | | | |
	Total (N=6943)	2/3 doses (N=1532)	4 doses (N=5014)	5+ doses (N=397)	p-value
Age at enrolment (median, IQR)	64 (53, 75)	45 (38, 56)	68 (58, 76)	68 (58, 74)	.
Age Group (N, %)					<.0001
<55	1972 (28.4)	1116 (72.8)	781 (15.6)	75 (18.9)	.
55-64	1762 (25.4)	246 (16.1)	1433 (28.6)	83 (20.9)	.
>=65	3209 (46.2)	170 (11.1)	2800 (55.8)	239 (60.2)	.
Gender (N, %)					<.0001
Male	3014 (43.4)	544 (35.5)	2255 (45.0)	215 (54.2)	.
Female	3929 (56.6)	988 (64.5)	2759 (55.0)	182 (45.8)	.
Original Vaccine type (N,%)					<.0001
Pfizer-BioNTech	3824 (55.1)	586 (38.3)	2891 (57.7)	347 (87.4)	.
Moderna	2620 (37.7)	691 (45.1)	1881 (37.5)	48 (12.1)	.
AstraZeneca/mRNA	499 (7.2)	255 (16.6)	242 (4.8)	<5*	.
Vaccine priority group (N,%)					<.0001
1. Individuals at increased risk	1599 (23.0)	288 (18.8)	974 (19.4)	337 (84.9)	.
2. Health care workers	590 (8.5)	270 (17.6)	311 (6.2)	9 (2.3)	.
3. General population	4754 (68.5)	974 (63.6)	3729 (74.4)	51 (12.8)	.

*Exact number not show due to small numbers

ENFORCE
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

Study visits

Table 3 gives the number and percentage of participants who have completed each of the six main study visits. The first participants enrolled returned for their 2 year study visit in February and this will continue over the next 6 months.

Table 3 Number and percentage of participants completing each of the main study visit

	Total (N=6943)
Visit 2 (prior to second vaccination) (N, %)	6534 (94.1)
Days from first vaccine to second study visit (median, IQR)	28 (21, 35)
Visit 3 (3 months after first vaccination) (N, %)	6032 (86.9)
Days from first vaccine to third study visit (median, IQR)	92 (89, 96)
Visit 4 (6 months after first vaccination) (N, %)	6072 (87.5)
Days from first vaccine to fourth study visit (median, IQR)	182 (179, 186)
Visit 5 (1 year after first vaccination) (N, %)	5638 (81.2)
Days from first vaccine to fifth study visit (median, IQR)	365 (361, 370)
Visit 6 (2 years after first vaccination) (N, %)	246 (3.5)
Days from first vaccine to sixth study visit (median, IQR)	726 (722, 729)

Withdrawal/Loss to follow-up

The number and percentage of participants discontinuing in the study is give in Table 4. A little under 10% have withdrawn from the study. However, we are still able to collect registry data from the majority of these participants.

Table 4 Number and percentage of participants discontinuing in the study

	Total (N=6943)
Study status (N, % of total)	
Still under follow-up	6260 (90.2)
Total withdrawn (N, % of total)	683 (9.8)

Outcomes

Primary outcome

From the multiantigen serological tests, the geometric mean (GM) and 95% confidence intervals (CI) for the antibody levels against the Receptor Binding Domain, and the complete Spike at each main study visit are reported in Table 5 (1st year of follow-up). Data from the 2 year study visit is not yet available.

Table 5 Presence of antibodies at study visit, Receptor-Binding Domain (RBD) and Spike antibody

	Total (N=6943)
AUH antibody data at visit 1 (enrolment) (N, % of total)	6874 (99.0)
AUH antibody data at visit 2 (prior to second vaccination) (N, % of total)	6290 (90.6)
AUH antibody data at visit 3 (3 months after first vaccination) (N, % of total)	5974 (86.0)
AUH antibody data at visit 4 (6 months after first vaccination) (N, % of total)	5952 (85.7)
AUH antibody data at visit 5 (1 year after first vaccination) (N, % of total)	5620 (80.9)
CoV-2 Receptor-Binding Domain (SERO)	
GM at enrolment (95%CI)	59 (57, 61)
GM at visit 2 (95%CI)	8845 (8407, 9306)
GM at visit 3 (95%CI)	94844 (91055, 98790)
GM at visit 4 (95%CI)	40205 (38626, 41849)
GM at visit 5 (95%CI)	313758 (305764, 321962)
CoV-2 Spike antibody (SERO)	
GM at enrolment (95%CI)	106 (102, 110)
GM at visit 2 (95%CI)	26878 (25644, 28171)
GM at visit 3 (95%CI)	172620 (166825, 178616)
GM at visit 4 (95%CI)	83361 (80464, 86362)
GM at visit 5 (95%CI)	401111 (393812, 408545)

GM: Geometric Mean

ENFORCE
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

Secondary outcome

The secondary outcome of breakthrough infections is monitored in two different ways. The number of participants testing positive for SARS-CoV-2, as reported via KIDS, and by serological monitoring (detection of SARS-CoV-2 nucleocapsid antibodies). The number of participants experiencing a positive PCR test following their first vaccination is reported in Table 6.

We are still developing the definition for breakthrough infection based on SARS-CoV-2 nucleocapsid antibodies. However, Table 7 shows the number and percentage with nucleocapsid titers >3000 U/mL at each main study visit. Nucleocapsid data from the 2 year study visit is not yet available.

Table 6 Number of participants testing positive for SARS-CoV-2

	Total (N=6943)
Ever tested for SARS-CoV-2 reported via KIDS (N, % of total)	6640 (95.6)
Number of PCR tests since first vaccine dose (median, IQR)	5 (2, 10)
Number of antigen tests since first vaccine dose (median, IQR)	3 (1, 7)
Number PCR positive for SARS-CoV-2 reported via KIDS (N, % of total)	3374 (48.6)
Days from first vaccine dose to SARS-CoV2 positive test (median, IQR)	312 (258, 352)
Age Group (n, % in category)	
<55	1269 (64.4)
55-64	869 (49.3)
>=65	1236 (38.5)
Gender (n, % in category)	
Male	1388 (46.1)
Female	1986 (50.5)

ENFORCE
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

Table 7 Number of participants with nucleocapsid titers >3000 U/mL at each main study visit

	Total (N=6943)
CoV-2 Nucleocapsid (SERO)	
Enrolment (n, %)	
<=3000	6165 (89.8)
>3000	702 (10.2)
Visit 2 (n, %)	
<=3000	5609 (89.2)
>3000	676 (10.8)
Visit 3 (n, %)	
<=3000	5205 (87.1)
>3000	770 (12.9)
Visit 4 (n, %)	
<=3000	5076 (85.4)
>3000	871 (14.6)
Visit 5 (n, %)	
<=3000	2594 (46.2)
>3000	3026 (53.8)

Fourth Vaccine Dose

Demographics

Table 8 gives an overview of the participant demographics among individuals who have received a 4th vaccine dose, stratified by the type of vaccine they received.

The majority have received a bivalent vaccine for their 4th dose, with 52% (n=2813) receiving the bivalent omicron BA4/5 and 37% (n=2028) receiving the bivalent omicron BA1 (either Moderna n=786, or Pfizer n=1242). Individuals who did not receive a bivalent vaccine for their 4th dose were those in the increased risk vaccine priority group who received their 4th dose earlier before the bivalent vaccines were available.

Table 8 Participant demographics among those who received a 4th dose, by 4th vaccine type

		4th Vaccine type		
	Total (N=5411)	Original (N=570)	Bivalent BA1 (N=2028)	Bivalent BA4/5 (N=2813)
Number of persons (%)				
Age Group				
<55	856 (15.8)	137 (24.0)	160 (7.9)	559 (19.9)
55-64	1516 (28.0)	121 (21.2)	486 (24.0)	909 (32.3)
>=65	3039 (56.2)	312 (54.7)	1382 (68.1)	1345 (47.8)
Gender				
Male	2470 (45.6)	289 (50.7)	949 (46.8)	1232 (43.8)
Female	2941 (54.4)	281 (49.3)	1079 (53.2)	1581 (56.2)
Vaccine priority group				
1. Individuals at increased risk	1311 (24.2)	434 (76.1)	356 (17.6)	521 (18.5)
2. Health care workers	320 (5.9)	13 (2.3)	57 (2.8)	250 (8.9)
3. General population	3780 (69.9)	123 (21.6)	1615 (79.6)	2042 (72.6)
Vaccine group				
Pfizer/BioNTech	3238 (59.8)	473 (83.0)	1141 (56.3)	1624 (57.7)
Moderna	1929 (35.6)	85 (14.9)	847 (41.8)	997 (35.4)
Adenoviral Vector/mRNA	244 (4.5)	12 (2.1)	40 (2.0)	192 (6.8)
Median (interquartile range, IQR)				
Age at enrolment (years)	68 (58, 76)	66 (55, 74)	71 (62, 79)	64 (56, 74)
Enrolment date	APR21 (MAR21, MAY21)	MAR21 (MAR21, MAR21)	APR21 (MAR21, MAY21)	APR21 (MAR21, MAY21)

Study visits

Of the 5411 participants who have received a 4th vaccine dose, 2740 (51%) had a study visit prior to their 4th dose and 3499 (65%) have had a study visit a median of 29 days after their 4th dose, 2666 (49%) had both a pre and post vaccine visit (Table 9).

Table 9 Number and percentage of participants completing 4th dose study visits

		Vaccine type		
	Total (N=5411)	Original (N=570)	Bivalent BA1 (N=2028)	Bivalent BA4/5 (N=2813)
Received a fourth dose (N, %)	5411 (100)	570 (100)	2028 (100)	2813 (100)
Time between first and fourth dose (median, IQR)	543 (513, 564)	346 (333, 478)	544 (523, 560)	548 (521, 573)
Visit 4X (0-14 days prior to fourth dose) (N, %)	2740 (50.6)	110 (19.3)	1010 (49.8)	1620 (57.6)
Days from pre-fourth dose visit to fourth dose (median, IQR)	4 (1, 8)	3 (1, 6)	4 (1, 7)	4 (1, 8)
Visit 4Xc (28 days after fourth dose) (N, %)	3499 (64.7)	384 (67.4)	1230 (60.7)	1885 (67.0)
Days from fourth dose to post-booster visit(median, IQR)	29 (26, 32)	28 (26, 33)	29 (25, 33)	29 (26, 32)
Total withdrawn (N, % of total)	418 (7.7)	76 (13.3)	162 (8.0)	180 (6.4)

Outcomes

Primary outcome

The data from the ELISA (Wantai) before and after the 4th vaccine dose are shown in Table 10.

Table 10 Presence of antibodies before and after the 4th vaccine dose, ELISA (Wantai) from SSI

		4th Vaccine type		
	Total (N=5411)	Original (N=570)	Bivalent/Omicron BA1 (N=2028)	Bivalent/Omicron BA4/5 (N=2813)
SSI antibody data 0-14 days before fourth dose (N, % of total)	2602 (48.1)	110 (19.3)	947 (46.7)	1545 (54.9)
Wantai result prior to 4th dose (visit 4X)				
Positive	2592 (99.6)	107 (97.3)	944 (99.7)	1541 (99.7)
Days prior to fourth dose (median (IQR))	4 (1, 8)	3 (1, 6)	4 (1, 7)	4 (1, 8)
SSI antibody data 28 days after fourth dose (N, % of total)	3193 (59.0)	387 (68.5)	1118 (55.0)	1688 (60.0)
Wantai result after 4th dose (visit 4Xc)				
Positive	3096 (97.0)	360 (93.0)	1073 (96.0)	1663 (98.5)
Days after fourth dose (median (IQR))	29 (26, 32)	28 (26, 33)	29 (25, 33)	29 (26, 32)

From the multiantigen serological tests, the geometric mean (GM) and 95% confidence intervals (CI) for the antibody levels against the Receptor Binding Domain, the complete Spike protein and the Nucleocapsid before and after the 4th vaccine dose are reported in Table 11 from the original mesoscale assay and Table 12 from the omicron specific assay.

Table 11 Presence of antibodies before and after the 4th dose, Receptor-Binding Domain (RBD), Spike antibody and Nucleocapsid (original Mesoscale assay)

		4th Vaccine type		
	Total (N=5411)	Original (N=570)	Bivalent/Omicron BA1 (N=2028)	Bivalent/Omicron BA4/5 (N=2813)
AUH antibody data 0-14 days before fourth dose (N, % of total)	2644 (48.9)	117 (20.5)	946 (46.6)	1581 (56.2)
AUH antibody data 28 days after fourth dose (N, % of total)	3453 (63.8)	390 (68.4)	1219 (65.6)	1844 (65.6)
CoV-2 Receptor-Binding Domain (SERO)				
GM 0-14 days before fourth dose (95%CI)	244282 (234282, 254709)	121605 (81040, 182474)	239047 (223115, 256117)	260579 (248604, 273132)
GM 28 days after fourth dose (95%CI)	454576 (441378, 468168)	186043 (149119, 232110)	520644 (508741, 532825)	502002 (494278, 509847)
CoV-2 Spike antibody (SERO)				
GM 0-14 days before fourth dose (95%CI)	337754 (327320, 348521)	190768 (137692, 264303)	337931 (322016, 354632)	352228 (339780, 365133)
GM 28 days after fourth dose (95%CI)	494564 (484105, 505250)	264646 (222708, 314481)	534354 (529755, 538993)	536340 (532415, 540295)
CoV-2 Nucleocapsid (SERO)				
GM 0-14 days before fourth dose (95%CI)	5417 (4967, 5908)	3948 (2524, 6175)	4759 (4110, 5510)	5992 (5364, 6693)
GM 28 days after fourth dose (95%CI)	5639 (5266, 6038)	1875 (1503, 2340)	6122 (5479, 6841)	6741 (6156, 7382)

GM: Geometric mean

E N F O R C E
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

*Table 12 Presence of omicron specific antibodies before and after the **4th** dose, by 4th vaccine type*

		4th Vaccine type		
	Total *(N=5411)*	*Original* *(N=570)*	*Bivalent BA1* *(N=2028)*	*Bivalent BA4/5* *(N=2813)*
AUH omicron antibody data before fourth dose (N, % of total)	2625 (48.5)	50 (8.8)	990 (48.8)	1585 (56.3)
AUH omicron antibody data after fourth dose (N, % of total)	2892 (53.4)	73 (12.8)	1179 (58.1)	1640 (58.3)
Spike (wildtype)				
GM 0-14 days before fourth dose (95%CI)	809437 (768730, 852299)	732328 (474615, 1129978)	795660 (728434, 869089)	820751 (769866, 874998)
GM 28 days after fourth dose (95%CI)	2962158 (2869436, 3057875)	2221774 (1745280, 2828360)	3137642 (2986941, 3295946)	2878717 (2760108, 3002424)
Spike (B.1.1.529: BA.1)				
GM 0-14 days before fourth dose (95%CI)	183936 (174434, 193957)	165122 (104134, 261828)	180514 (164984, 197506)	186743 (174796, 199507)
GM 28 days after fourth dose (95%CI)	964525 (929253, 1001136)	668176 (503711, 886341)	1046241 (987498, 1108478)	924634 (880291, 971211)
Spike (B.1.1.529: BA.2)				
GM 0-14 days before fourth dose (95%CI)	243861 (230217, 258313)	231110 (144159, 370506)	233407 (211627, 257429)	251051 (233668, 269728)
GM 28 days after fourth dose (95%CI)	1124561 (1083703, 1166960)	807405 (611774, 1065592)	1112448 (1051136, 1177337)	1150189 (1094701, 1208490)
Spike (B.1.1.529: BA.3)				
GM 0-14 days before fourth dose (95%CI)	138683 (131442, 146322)	129101 (81988, 203285)	138049 (126014, 151233)	139395 (130392, 149020)
GM 28 days after fourth dose (95%CI)	741000 (712223, 770939)	557549 (412284, 753998)	807789 (759266, 859412)	705426 (669704, 743054)
Spike (B.1.1.529: BA.4)				
GM 0-14 days before fourth dose (95%CI)	241796 (228633, 255716)	216012 (136959, 340694)	233260 (212225, 256379)	248166 (231350, 266205)
GM 28 days after fourth dose (95%CI)	1210700 (1167891, 1255078)	812001 (611595, 1078075)	1187803 (1124138, 1255074)	1249452 (1191010, 1310762)
Spike (B.1.1.529: BA.5)				
GM 0-14 days before fourth dose (95%CI)	259294 (245281, 274107)	234363 (149050, 368507)	250228 (227871, 274777)	265969 (248050, 285183)
GM 28 days after fourth dose (95%CI)	1282722 (1237136, 1329987)	856406 (646322, 1134777)	1265868 (1197370, 1338285)	1318474 (1256629, 1383363)

Figure 2-Figure 7 show the distribution of the omicron specific assays on the log10 scale before and after the 4th vaccine dose. See Table 12 for the number of participants contributing data to each figure.

*Figure 2 Distribution of CoV-2 Spike **(Wildtype)** antibody levels before and after the **4th** vaccine dose*

*Figure 3 Distribution of CoV-2 Spike **(B.1.1.528: BA1)** antibody levels before and after the **4th** vaccine dose*

ENFORCE
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

*Figure 4 Distribution of CoV-2 Spike **(B.1.1.528: BA2)** antibody levels before and after the **4th** vaccine dose*


Spike (B.1.1.529: BA.2)

*Figure 5 Distribution of CoV-2 Spike **(B.1.1.528: BA3)** antibody levels before and after the **4th** vaccine dose*


*Figure 6 Distribution of CoV-2 Spike **(B.1.1.528: BA4)** antibody levels before and after the **4th** vaccine dose*

*Figure 7 Distribution of CoV-2 Spike **(B.1.1.528: BA5)** antibody levels before and after the **4th** vaccine dose*

Safety and Monitoring

It should be noted that a number of participants may have received influenza and pneumococcal vaccines at the same time as their 4th vaccine dose. We are currently unable to identify how many participants this relates to and so the safety outcomes reported here are potentially confounded by simultaneous vaccinations.

Local and systemic reactions

Table 13 outlines the number of participants reporting any local or systemic reactions within 2 weeks of their 4th vaccination. The total number of participants experiencing any symptoms are reported as well as the number experiencing each individual symptom. Note that participants can report multiple symptoms. The percentages are out of the total number of participants who had completed the symptoms form at the time of data extraction. Figure 8 Percentage of participants reporting systemic and local symptoms within 0-7 days of their **4th** dose of the vaccine, by 4th vaccine type shows the proportion reporting mild, moderate or severe symptoms by vaccine type.

ENFORCE
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

Table 13 Number & percentage reporting local/systemic reactions within 0-7 days and 8-14 days following a 4th vaccine dose, overall and by 4th vaccine type

|	Total		Original		Bivalent BA1		Bivalent BA4/5	
	First 7 days (N=3282)	8-14 days (N=3327)	First 7 days (N=353)	8-14 days (N=362)	First 7 days (N=1148)	8-14 days (N=1161)	First 7 days (N=1781)	8-14 days (N=1804)
Number of persons (%)								
Any clinical symptoms	1636 (49.8)	814 (24.5)	131 (37.1)	68 (18.8)	601 (52.4)	320 (27.6)	904 (50.8)	426 (23.6)
Any local symptoms at injection site	2394 (72.9)	550 (16.5)	239 (67.7)	42 (11.6)	835 (72.7)	213 (18.3)	1320 (74.1)	295 (16.4)
Symptoms reported								
Muscle pain	833 (25.9)	337 (10.2)	59 (17.0)	25 (7.0)	328 (29.1)	138 (12.0)	446 (25.5)	174 (9.7)
Joint pain	524 (16.4)	260 (7.9)	45 (13.0)	21 (5.8)	194 (17.5)	102 (8.9)	285 (16.5)	137 (7.7)
Fatigue	1211 (37.4)	607 (18.4)	97 (27.9)	53 (14.7)	430 (38.0)	243 (21.1)	684 (38.8)	311 (17.4)
Fever	386 (12.1)	93 (2.8)	39 (11.3)	15 (4.2)	143 (12.8)	32 (2.8)	204 (11.8)	46 (2.6)
Headache	771 (24.1)	376 (11.4)	59 (17.1)	33 (9.1)	290 (26.0)	144 (12.6)	422 (24.2)	199 (11.2)
Nausea	256 (8.1)	119 (3.6)	22 (6.4)	9 (2.5)	105 (9.5)	44 (3.9)	129 (7.5)	66 (3.7)
Chills	384 (12.1)	112 (3.4)	33 (9.6)	13 (3.6)	153 (13.8)	41 (3.6)	198 (11.4)	58 (3.3)
Local symptoms at injection site								
Redness	432 (13.8)	102 (3.1)	37 (10.8)	10 (2.8)	185 (17.0)	52 (4.6)	210 (12.4)	40 (2.3)
Swelling	638 (20.4)	137 (4.2)	38 (11.0)	11 (3.1)	254 (23.3)	58 (5.1)	346 (20.5)	68 (3.9)
Tenderness	2343 (72.1)	526 (16.0)	235 (66.8)	40 (11.2)	814 (71.9)	199 (17.5)	1294 (73.3)	287 (16.1)
Median (interquartile range, IQR)								
Number of symptom boxes completed	10 (10, 10)	10 (10, 10)	10 (10, 10)	10 (10, 10)	10 (10, 10)	10 (10, 10)	10 (10, 10)	10 (10, 10)

ENFORCE
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

*Figure 8 Percentage of participants reporting systemic and local symptoms within 0-7 days of their **4th** dose of the vaccine, by 4th vaccine type*

ENFORCE
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

1

Local reactions by vaccine type (4th dose)
Original (First 7 days n=353, 8-14 days n=362), Bivalent BA1 (First 7 days n=1148, 8-14 days n=1161), Bivalent BA4/5
(First 7 days n=1781, 8-14 days n=1804)

E N F O R C E
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

Adverse and Serious Adverse Events

This section gives an overview of the AEs (Table 14) and SAEs (Table 15) reported following the 4th vaccine dose.

*Table 14 Overview of AEs reported (grade 3 and grade 4) following the 4th dose, by **4th** vaccine*

		4th Vaccine type		
	Total (N=5411)	*Original (N=570)*	*Bivalent BA1 (N=2028)*	*Bivalent BA4/5 (N=2813)*
Number of persons (%)				
At least one Adverse Event reported	177 (3.3)	32 (5.6)	62 (3.1)	83 (3.0)

*Table 15 Overview and current status of SAEs reported following the 4th dose, by **4th** vaccine*

		4th Vaccine type		
	Total (N=5411)	*Original (N=570)*	*Bivalent BA1 (N=2028)*	*Bivalent BA4/5 (N=2813)*
Total number of participants reporting any SAE (N, %)	21 (0.4)	7 (1.2)	5 (0.2)	9 (0.3)
Total number of SAE reported (N, % of SAE)	21 (100)	7 (100)	5 (100)	9 (100)

Fifth Vaccine Dose

Demographics

Table 16 gives an overview of the participant demographics among individuals who have received a 5th vaccine dose, stratified by the type of vaccine they received.

The majority 94% (n=373) have received a bivalent vaccine for their 5th dose.

Table 16 Participant demographics among those who received a 5th dose, by 5th vaccine type

		5th Vaccine type		
	Total (N=397)	Original (N=24)	Bivalent BA1 (N=137)	Bivalent BA4/5 (N=236)
Number of persons (%)				
Age Group				
<55	75 (18.9)	5 (20.8)	16 (11.7)	54 (22.9)
55-64	83 (20.9)	5 (20.8)	27 (19.7)	51 (21.6)
>=65	239 (60.2)	14 (58.3)	94 (68.6)	131 (55.5)
Gender				
Male	215 (54.2)	14 (58.3)	82 (59.9)	119 (50.4)
Female	182 (45.8)	10 (41.7)	55 (40.1)	117 (49.6)
Vaccine priority group				
1. Individuals at increased risk	337 (84.9)	21 (87.5)	120 (87.6)	196 (83.1)
2. Health care workers	9 (2.3)	<5*	<5*	6 (2.5)
3. General population	51 (12.8)	<5*	14 (10.2)	34 (14.4)
Original Vaccine group				
Pfizer/BioNTech	347 (87.4)	20 (83.3)	119 (86.9)	208 (88.1)
Moderna	48 (12.1)	<5*	18 (13.1)	26 (11.0)
Adenoviral Vector/mRNA	<5*	<5*	<5*	<5*
Median (interquartile range, IQR)				
Age at enrolment (years)	68 (58, 74)	68 (59, 72)	70 (60, 75)	66 (56, 73)
Enrolment date	MAR21 (FEB21, MAR21)	MAR21 (MAR21, MAR21)	MAR21 (FEB21, MAR21)	MAR21 (FEB21, MAR21)

*Exact number not shown due to small numbers

ENFORCE
Danish National Cohort Study of
Effectiveness and Safety of
SARS-CoV-2 vaccines

Study visits

Of the 397 participants who have received a 5th vaccine dose, 157 (40%) had a study visit prior to their 5th dose and 241 (61%) have had a study visit a median of 29 days after their 5th dose, 154 (39%) had both a pre and post vaccine visit.

Table 17 Number and percentage of participants completing 5th dose study visits

	Total (N=397)	Vaccine type		
		Original (N=24)	Bivalent BA1 (N=137)	Bivalent BA4/5 (N=236)
Received a fifth dose (N, %)	397 (100)	24 (100)	137 (100)	236 (100)
Time between first and fifth dose (median, IQR)	584 (569, 596)	533 (497, 577)	579 (564, 585)	591 (576, 604)
Visit 5X (0-14 days prior to fifth dose) (N, %)	157 (39.5)	6 (25.0)	48 (35.0)	103 (43.6)
Days from pre-fifth dose visit to fifth dose (median, IQR)	4 (1, 8)	4 (1, 7)	4 (1, 7)	6 (1, 10)
Visit 5Xc (28 days after fifth dose) (N, %)	241 (60.7)	14 (58.3)	83 (60.6)	144 (61.0)
Days from fifth dose to post-booster visit(median, IQR)	29 (26, 33)	29 (27, 33)	29 (24, 33)	29 (26, 33)
Total withdrawn (N, % of total)	49 (12.3)	5 (20.8)	16 (11.7)	28 (11.9)

Outcomes

Primary outcome

From the multiantigen serological tests, the geometric mean (GM) and 95% confidence intervals (CI) for the antibody levels against the Receptor Binding Domain, the complete Spike protein and the Nucleocapsid before and after the 5th vaccine dose are reported in Table 18 from the original mesoscale assay. Only 5 participants with a pre and 18 participants with a post vaccine visit had samples analyzed by the omicron specific assay, so this data is not shown.

*Table 18 Presence of antibodies before and after the **5th dose**, Receptor-Binding Domain (RBD), Spike antibody and Nucleocapsid (original Mesoscale assay)*

		5th Vaccine type		
	Total (N=397)	Original (N=24)	Bivalent BA1 (N=137)	Bivalent BA4/5 (N=236)
AUH antibody data 0-14 days before fifth dose (N, % of total)	153 (38.5)	<5*	47 (34.3)	102 (43.2)
AUH antibody data 28 days after fifth dose (N, % of total)	239 (60.2)	14 (58.3)	84 (61.3)	141 (59.7)
CoV-2 Receptor-Binding Domain (SERO)				
GM 0-14 days before fifth dose (95%CI)	92375 (64750, 131786)	NA	100910 (54911, 185441)	86809 (55000, 137016)
GM 28 days after fifth dose (95%CI)	197653 (153580, 254373)	126048 (29110, 545806)	163518 (100170, 266927)	231394 (173629, 308378)
CoV-2 Spike antibody (SERO)				
GM 0-14 days before fifth dose (95%CI)	163026 (123148, 215818)	NA	191269 (124858, 293004)	148266 (102003, 215512)
GM 28 days after fifth dose (95%CI)	293183 (243379, 353179)	200126 (63743, 628306)	276624 (199366, 383820)	315244 (250716, 396380)
CoV-2 Nucleocapsid (SERO)				
GM 0-14 days before fifth dose (95%CI)	2275 (1622, 3189)	NA	1874 (1016, 3457)	2523 (1647, 3865)
GM 28 days after fifth dose (95%CI)	3118 (2391, 4066)	2064 (738, 5774)	2137 (1409, 3241)	4068 (2832, 5843)

NA: not analyzed as <5 participants contributing data

Safety and Monitoring

It should be noted that a number of participants may have received influenza and pneumococcal vaccines at the same time as their 5th vaccine dose. We are currently unable to identify how many participants this relates to and so the safety outcomes reported here are potentially confounded by simultaneous vaccinations.

Local and systemic reactions

Table 19 outlines the number of participants reporting any local or systemic reactions within 7 days of their 5th vaccination. The total number of participants experiencing any symptoms are reported as well as the number experiencing each individual symptom. Figure 9 shows the proportion reporting mild, moderate or severe symptoms by vaccine type.

Table 19 Number & percentage reporting local/systemic reactions within 0-7 days and 8-14 days following a 5th vaccine dose, overall and by 5th vaccine type

	Total		Original		Bivalent BA1		Bivalent BA4/5	
	First 7 days (N=122)	8-14 days (N=232)	First 7 days (N=10)	8-14 days (N=15)	First 7 days (N=46)	8-14 days (N=80)	First 7 days (N=66)	8-14 days (N=137)
Number of persons (%)								
Any clinical symptoms	46 (37.7)	61 (26.3)	7 (70.0)	4 (26.7)	16 (34.8)	16 (20.0)	23 (34.8)	41 (29.9)
Any local symptoms at injection site	83 (68.0)	42 (18.1)	5 (50.0)	3 (20.0)	30 (65.2)	11 (13.8)	48 (72.7)	28 (20.4)

Figure 9 Percentage of participants reporting systemic and local symptoms within 0-7 days of their **5th dose** of the vaccine, by vaccine type

Local reactions by vaccine type (5th dose)
Original (First 7 days n=10, 8-14 days n=15), Bivalent BA1 (First 7 days n=46, 8-14 days n=80), Bivalent BA4/5 (First 7 days n=66, 8-14 days n=137)

Adverse and Serious Adverse Events

This section gives an overview of the AEs (Table 20) and SAEs (Table 21) reported following 5th vaccine dose.

Table 20 Overview of AEs reported (grade 3 and grade 4) by 5th vaccine

		5th Vaccine type		
	Total (N=397)	*Original (N=24)*	*Bivalent BA1 (N=137)*	*Bivalent BA4/5 (N=236)*
Number of persons (%)				
At least one Adverse Event reported	25 (6.3)	<5*	5 (3.6)	18 (7.6)

*Exact numbers not shown due to small numbers

Table 21 Overview and current status of SAEs reported by 5th vaccine

		5th Vaccine type		
	Total (N=397)	*Original (N=24)*	*Bivalent BA1 (N=137)*	*Bivalent BA4/5 (N=236)*
Total number of participants reporting any SAE (N, %)	8 (2.0)	<5*	<5*	5 (2.1)
Total number of SAE reported (N, % of SAE)	8 (100)	<5*	<5*	5 (100)

*Exact numbers not shown due to small numbers

Deaths

There have been 90 deaths reported in the study thus far. Eight were reported as a SAE but none had a reasonable probability of relatedness to vaccination nor were reported as a SUSAR. There were an additional 82 deaths recorded in the CPR registry that were outside of the period for reporting SAE (Table 22).

Table 22 Characteristics of participants who have died

	Total (N=90)
Number of persons (%)	
Age Group	
<55	7 (7.8)
55-64	16 (17.8)
>=65	67 (74.4)
Gender	
Male	49 (54.4)
Female	41 (45.6)
Death reported as an SAE	
Yes	8 (8.9)
No	82 (91.1)
Reasonable probability of relatedness to vaccination	
No	8 (100)
Median (interquartile range, IQR)	
Age at enrolment (years)	75 (64, 80)
Time from first vaccine dose (days)	375 (268, 522)